Houston Rx LLC

Has Houston Rx LLC received an FDA warning letter about GLP-1 drugs?

No FDA warning letter to Houston Rx LLC naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 1 drug recall report for it naming tirzepatide, the latest initiated Sep 25, 2026.

FDA records in this index name Houston Rx LLC on Sep 25, 2026.

Type named in FDA records
Not stated
FDA warning letters
0
Drug recall reports
1
Drugs named
Tirzepatide
Latest record
Sep 25, 2026

FDA warning letters

No FDA warning letters in this index.

Drug recalls

Record
Sep 25, 2026Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.Lack of assurance of sterility.Class IIOngoingD-0040-2027

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

Houston Rx LLC, Houston, TX (503A)

1 listed action, including 1 Form 483 (2026).

Document
Aug 28, 2026Form 483483 Issued 08/28/2026fda.gov

A Form 483 lists investigator observations, not a final FDA determination.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Houston Rx LLC, Houston, TX.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.